Natural killer cell therapy - Shenzhen Hank Bioengineering Institute

Drug Profile

Natural killer cell therapy - Shenzhen Hank Bioengineering Institute

Alternative Names: HANK cell - Shenzhen Hank Bioengineering Institute; High-activity natural killer cells - Shenzhen Hank Bioengineering Institute; Natural killer immunotherapy - Shenzhen Hank Bioengineering Institute

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator HANK Bioengineering
  • Developer Fuda Cancer Hospital; HANK Bioengineering
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II B cell lymphoma; Breast cancer; Cervical cancer; Colorectal cancer; Laryngeal cancer; Liver cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Pharyngeal neoplasms; Renal cancer; Soft tissue sarcoma; Tongue cancer

Most Recent Events

  • 01 Dec 2016 Phase-I/II clinical trials in Colorectal cancer (Second-line therapy or greater, Metastatic disease, Recurrent) in China (IV) (NCT03008499)
  • 01 Dec 2016 Phase-I/II clinical trials in Liver cancer (Second-line therapy or greater, Recurrent) in China (IV) (NCT03008343)
  • 01 Dec 2016 Phase-I/II clinical trials in Malignant melanoma (Metastatic disease, Second-line therapy or greater, Recurrent) in China (IV) (NCT03007823)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top